Janux Therapeutics JANX Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's free cash flow margin?
- Janux Therapeutics (JANX) reported free cash flow margin of -571.6% in Q1 2026.
- How has Janux Therapeutics's free cash flow margin changed year-over-year?
- Janux Therapeutics's free cash flow margin decreased by 14.7% year-over-year, from -498.4% to -571.6%.
- What is the long-term trend for Janux Therapeutics's free cash flow margin?
- Over 4 years (2021 to 2025), Janux Therapeutics's free cash flow margin has grown at a 13.2% compound annual growth rate (CAGR), from -507.5% to -832.8%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.